Advertisement

The Scientist

» drug safety, immunology and disease/medicine

Most Recent

image: ALS Drug Access Debated

ALS Drug Access Debated

By | April 7, 2015

Biotech company Genervon has requested accelerated approval for its experimental ALS drug after a small but promising Phase 2 trial. Patients advocate for its acceptance, while researchers urge caution.

2 Comments

image: Studying Ebola Survivors

Studying Ebola Survivors

By | April 6, 2015

A scientist jumps at the chance to study the blood of four Ebola survivors to better understand how the immune system responds to the deadly virus. 

1 Comment

image: Study: Ebola Predictions Overstated

Study: Ebola Predictions Overstated

By | April 2, 2015

Most forecasting methods used to predict the extent of the Ebola outbreak in West Africa overestimated the epidemic’s reach, an updated analysis shows.

0 Comments

image: Cancer Immunotherapist

Cancer Immunotherapist

By | April 1, 2015

Scientist to Watch Yvonne Saenger explains recent advances in using biomarkers to identify cancer patients who might benefit most from immunotherapy.

0 Comments

image: Contributors

Contributors

By | April 1, 2015

Meet some of the people featured in the April 2015 issue of The Scientist.

0 Comments

image: Control ALT, Delete Cancer

Control ALT, Delete Cancer

By , , and | April 1, 2015

Treating cancer by shutting down the alternative lengthening of telomeres (ALT) pathway

1 Comment

image: In Custody

In Custody

By | April 1, 2015

Expert tips for isolating and culturing cancer stem cells

1 Comment

image: Manipulative Microbiomes

Manipulative Microbiomes

By | April 1, 2015

Gut bacteria control tumor growth via the mammalian immune system.

3 Comments

image: Professional Marksman

Professional Marksman

By | April 1, 2015

Charles Sawyers, who began his research career just as the genetic details of human oncogenes were emerging, codeveloped Gleevec, the quintessential targeted cancer therapy.

0 Comments

image: The CAR T-Cell Race

The CAR T-Cell Race

By | April 1, 2015

Tumor-targeting T-cell therapies are generating remarkable remissions in hard-to-beat cancers—and attracting millions of dollars of investment along the way.

1 Comment

Advertisement

Popular Now

  1. Opinion: Too Many Mitochondrial Genome Papers
  2. Antibiotics and the Gut Microbiome
  3. Sex Differences in Pain Pathway
  4. The Brain on Fear
    The Scientist The Brain on Fear

    Scientists uncover the neurons in the mouse brain responsible for linking the sight of a looming object to scared behavior.

Advertisement
Eppendorf
Eppendorf
Advertisement
The Scientist